Emyria (ASX:EMD) has received approval from Health Canada to begin importating MDMA into Australia.
The $23.36 million market capitalisation company has received all necessary Health Canada export permits and has confirmed all regulatory requirements.
This ‘significant’ development follows the start of dosing for Emyria’s MDMA-assisted therapy program, believed to be a first for a private specialist clinic in Australia.
Commenting on the approved importation, Emyria Chief Executive Officer (CEO) Dr Michael Winlo says: “As a leading private specialist clinic in Australia, we’ve achieved a significant milestone with the initiation of active MDMA-assisted therapy.
we’ve achieved a significant milestone with the initiation of active MDMA-assisted therapy
Our initial MDMA supply for up to 70 patients, combined with our steady progress towards Authorised Prescriber status, underscores our commitment to exploring promising treatments for PTSD sufferers and elevating mental health care outcomes in Australia.”
The company’s MDMA supply is sufficient for up to 70 patients and is pivotal for the company’s ethics-approved therapy trial and, potentially, direct patient care if specialists received Authorised Prescriber (AP) status from the TGA.
Emyria is a clinical services and drug development company focused on revolutionising patient outcomes in neuroscience and mental health.
Write to Aaliyah Rogan at Mining.com.au
Images: Emyria
